CN110742862A - Astaxanthin emulsion and preparation method thereof - Google Patents
Astaxanthin emulsion and preparation method thereof Download PDFInfo
- Publication number
- CN110742862A CN110742862A CN201911110978.2A CN201911110978A CN110742862A CN 110742862 A CN110742862 A CN 110742862A CN 201911110978 A CN201911110978 A CN 201911110978A CN 110742862 A CN110742862 A CN 110742862A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- fish oil
- water
- emulsion
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 81
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 81
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 81
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 81
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 81
- 239000000839 emulsion Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000004945 emulsification Methods 0.000 title claims description 12
- 235000021323 fish oil Nutrition 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 238000001647 drug administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000276707 Tilapia Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000021032 oily fish Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an astaxanthin emulsion and a preparation method thereof, belonging to the technical field of astaxanthin application, wherein the astaxanthin emulsion comprises astaxanthin, fish oil and water; the ratio of the astaxanthin to the fish oil to the water is 3g (40-60) mL; the preparation method of the astaxanthin emulsion comprises the following steps: mixing astaxanthin, fish oil and water, homogenizing and emulsifying. The area under the curve (AUC) of the astaxanthin emulsion during drug administration(0‑∞)) The curve Area (AUC) was 389.213 mg/L.multidot.h for the astaxanthin aqueous solution of the control group(0‑∞)) 280.753 mg/L.h; can see the original hairThe bioavailability of the astaxanthin emulsion is far higher than that of an astaxanthin water solution.
Description
Technical Field
The invention belongs to the technical field of astaxanthin application, and particularly relates to an astaxanthin emulsion and a preparation method thereof.
Background
Astaxanthin, also known as astaxanthin, is a carotenoid, is also the highest-grade product of carotenoid synthesis, is dark pink, has a chemical structure similar to β -carotene, β -carotene, lutein, canthaxanthin, lycopene and the like are all intermediate products of carotenoid synthesis, and has the strongest oxidation resistance in the natural world.
Astaxanthin is used as a natural colorant, a feed additive and a health care nutritional product, is widely applied to the industries of food, medicine and cosmetics, and is also applied to the aquaculture industry.
But the bioavailability of astaxanthin is low at present.
Disclosure of Invention
In view of the above, the present invention aims to provide an astaxanthin emulsion capable of improving the bioavailability of astaxanthin and a preparation method thereof.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides an astaxanthin emulsion, which comprises astaxanthin, fish oil and water; the ratio of the astaxanthin to the fish oil to the water is 3g (40-60) mL.
Preferably, the ratio of the astaxanthin to the fish oil to the water is 3g (45-55) mL.
Preferably, the ratio of the astaxanthin to the fish oil to the water is 3g:50mL:50 mL.
Preferably, the water is distilled water.
The invention provides a preparation method of an astaxanthin emulsion, which comprises the following steps: mixing astaxanthin, fish oil and water, homogenizing and emulsifying.
Preferably, the rotation speed of the homogeneous emulsification is 15000-25000 rpm; the homogenizing and emulsifying time is 3-8 min.
Preferably, the rotation speed of the homogeneous emulsification is 18000-22000 rpm; the homogenizing and emulsifying time is 4-6 min.
The invention has the beneficial effects that: the astaxanthin emulsion provided by the invention comprises astaxanthin, fish oil and water; the ratio of the astaxanthin to the fish oil to the water is 3g (40-60) mL. Mixing the astaxanthin, the fish oil and water, homogenizing and emulsifying to obtain an astaxanthin emulsion; the astaxanthinThe emulsion has high bioavailability. According to the description of the examples, the area under the curve (AUC) of the emulsion of astaxanthin provided by the present invention when administered(0-∞)) The curve Area (AUC) was 389.213 mg/L.multidot.h for the astaxanthin aqueous solution of the control group(0-∞)) 280.753 mg/L.h; the bioavailability of the astaxanthin emulsion provided by the invention is far higher than that of an astaxanthin aqueous solution.
Detailed Description
The invention provides an astaxanthin emulsion, which comprises astaxanthin, fish oil and water; the ratio of the astaxanthin to the fish oil to the water is 3g (40-60) mL.
In the invention, the ratio of the astaxanthin to the fish oil to the water is preferably 3g (45-55) mL, and more preferably 3g (50 mL) to 50 mL.
The source and specification of the astaxanthin are not particularly limited in the invention, and the astaxanthin product which is conventional in the field can be adopted, and in the specific implementation process of the invention, the astaxanthin is purchased from Dalian Meilun biotechnology limited company and 100 mg/bottle.
The fish oil is grease extracted from oily fish tissues, contains rich fatty acid components, and is mainly divided into saturated fatty acid, monounsaturated fatty acid and polyunsaturated fatty acid (PUFAs) according to the saturation degree of a hydrocarbon chain. The fish oil is rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA, commonly called NAOHUANGJIN) and various n-3 series polyunsaturated fatty acids (n-3 PUFA). In the invention, the fish oil plays a role in emulsification, so that the whole system forms stable emulsion.
The source and specification of the fish oil are not particularly limited in the invention, and the fish oil is prepared by using a fish oil product which is conventional in the field, and in the specific implementation process of the invention, the fish oil is preferably AscentaNutraSea Omega-3 liquid fish oil which is purchased from Nutrisea corporation of Canada, wherein each 1mL of the fish oil contains 150mg of EPA and 100mg of DHA. In the present invention, the water is preferably distilled water.
The invention provides a preparation method of an astaxanthin emulsion, which comprises the following steps: mixing astaxanthin, fish oil and water, homogenizing and emulsifying.
The mixing method is not particularly limited, and conventional mixing can be adopted. In the invention, the rotation speed of the homogeneous emulsification is preferably 15000-25000 rpm, more preferably 18000-22000 rpm, and most preferably 20000 rpm; the time for homogenizing and emulsifying is preferably 3-8 min, more preferably 4-6 min, and most preferably 5 min. In the present invention, the homogenizing emulsification is preferably performed using a homogenizer; the brand and specification of the homogenizer are not particularly limited, and the homogenizer can be a conventional homogenizer in the field.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
(1) Emulsification of astaxanthin: 4.5g of astaxanthin, 75mL of fish oil and 75mL of distilled water were put in a beaker and emulsified by a homogenizer (20000rpm, 5min for homogenization) to obtain a mixture containing 30mg of astaxanthin and 0.5mL of fish oil per 1mL of the emulsion.
4.5g of astaxanthin and 150mL of distilled water were placed in a beaker and mixed by a homogenizer to obtain a mixture containing 30mg of astaxanthin per 1mL of the mixture.
Astaxanthin (available from Dalian Meiren Biotechnology Ltd., 100 mg/bottle). Fish oil (Ascenta NutraSea omega-3 liquid fish oil containing EPA 150mg and DHA 100mg per 1 ml) from Nutrisea, Canada.
(2) Temporarily breeding experimental animals: before the experiment, the tilapia is cultured in a 200L culture tank, a circulating water culture system is used, and the water temperature is 28 +/-1 ℃. During the period, the tilapia is sampled to detect that no astaxanthin residue exists in the body, the experiment is started after temporary rearing for 7d, the experimental fish is weighed by tail before administration, and the average weight is (451.5 +/-67.8) g.
(3) The experimental scheme is as follows: the experimental group adopts a conventional therapeutic dose of 30mg/kg and a catheter to fill astaxanthin emulsion in a single mouth, and blood samples of tilapia are respectively collected at 0.25, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36 and 48 hours after administration.
The control group is infused with astaxanthin mixed solution in a catheter in a single time at a conventional therapeutic dose of 30mg/kg, and blood samples of tilapia are respectively collected at 0.25, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36 and 48 hours after administration.
Blood was collected by tail-bleed using a 2mL syringe and placed in a 5mL centrifuge tube, which was rinsed with 0.1% sodium heparin and air dried before use. The blood was centrifuged at 4000rpm for 10min, the supernatant was taken and the sample stored at-80 ℃.
(4) Extracting astaxanthin: 1mL of plasma was taken and the sample was placed in a 10mL centrifuge tube. Adding 3mL acetonitrile, vortexing for 5min, centrifuging at 10000rpm for 5min, and taking supernatant in a wide-mouth bottle. Repeating the above extraction steps for 2 times, and mixing the supernatants. The jars were placed in a water bath (50 ℃) and air dried in a fume hood. After the sample was drained, 2mL of the mobile phase solution was added and the mixture was shaken on a shaker until it was completely dissolved. 2mL of n-hexane was added thereto, and the mixture was shaken for 5 min. All solutions are transferred into a 10mL centrifuge tube, centrifuged at 10000rpm for 5min, 1mL of the lower layer solution is transferred into a 15mL centrifuge tube, diluted by 10 times with mobile phase, filtered by a 0.22 μm microporous membrane and stored in a sample bottle for testing.
(5) Detection conditions are as follows: high performance liquid chromatograph: agilent 1260; a chromatographic column: agilent ZORBAX-C18150X 4.6 mm; column temperature: 30 ℃; mobile phase: acetonitrile-methanol-95: 5 (V/V); detection wavelength: 474 nm; sample introduction amount: 10 μ L.
(6) And (3) result and data processing: area under the time curve (AUC)(0-∞)) Reflects the total amount of the medicine in blood and also reflects the absorption degree grade bioavailability of the medicine. From the control group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) 280.753 mg/L.h; from the experimental group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) The concentration was 389.213mg/L · h.
TABLE 1 astaxanthin concentration in samples at different sampling times
Example 2
(1) Emulsification of astaxanthin: 4.5g of astaxanthin, 90mL of fish oil and 90mL of distilled water were put in a beaker and emulsified by a homogenizer (20000rpm, 5min for homogenization) to obtain a mixture containing 25mg of astaxanthin per 1mL of the emulsion and 0.5mL of fish oil.
4.5g of astaxanthin and 180mL of distilled water were placed in a beaker and mixed by a homogenizer to obtain a mixture containing 25mg of astaxanthin per 1mL of the mixture.
Astaxanthin (available from Dalian Meiren Biotechnology Ltd., 100 mg/bottle). Fish oil (Ascenta NutraSea omega-3 liquid fish oil containing EPA 150mg and DHA 100mg per 1 ml) from Nutrisea, Canada.
See example 1 for animal experimental methods and results as follows: from the control group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) 261.563 mg/L.h; from the experimental group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) The concentration was 369.391mg/L · h.
Example 3
(1) Emulsification of astaxanthin: 4.5g of astaxanthin, 60mL of fish oil, and 60mL of distilled water were put in a beaker, and emulsified by a homogenizer (20000rpm, 5min for homogenization) to obtain an emulsion containing 37.5mg of astaxanthin and 0.5mL of fish oil per 1mL of the emulsion.
4.5g of astaxanthin and 120mL of distilled water were put in a beaker and mixed by a homogenizer to obtain a mixture containing 37.5mg of astaxanthin per 1mL of the mixture.
Astaxanthin (available from Dalian Meiren Biotechnology Ltd., 100 mg/bottle). Fish oil (Ascenta NutraSea omega-3 liquid fish oil containing EPA 150mg and DHA 100mg per 1 ml) from Nutrisea, Canada.
See example 1 for animal experimental methods and results as follows: from the control group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) 252.453 mg/L.h; from the experimental group results, the area under the curve (AUC) of the drug time was analyzed using DAS3.0 software(0-∞)) Is 348.315 mg/L.h。
From the above examples, it can be seen that the bioavailability of the astaxanthin emulsion described in this application is much higher than that of the astaxanthin aqueous solution.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (7)
1. An astaxanthin emulsion, which is characterized by comprising astaxanthin, fish oil and water; the ratio of the astaxanthin to the fish oil to the water is 3g (40-60) mL.
2. The astaxanthin emulsion according to claim 1, wherein the ratio of astaxanthin, fish oil and water is 3g (45-55) mL.
3. The astaxanthin emulsion according to claim 2, wherein the ratio of astaxanthin, fish oil and water is 3g:50 mL.
4. An emulsion of astaxanthin according to claim 1, characterized in that the water is distilled water.
5. A method of producing an astaxanthin emulsion according to any one of claims 1 to 4, comprising the steps of: mixing astaxanthin, fish oil and water, homogenizing and emulsifying.
6. The preparation method according to claim 5, wherein the rotation speed of the homogeneous emulsification is 15000-25000 rpm; the homogenizing and emulsifying time is 3-8 min.
7. The preparation method according to claim 6, wherein the rotation speed of the homogeneous emulsification is 18000-22000 rpm; the homogenizing and emulsifying time is 4-6 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911110978.2A CN110742862A (en) | 2019-11-14 | 2019-11-14 | Astaxanthin emulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911110978.2A CN110742862A (en) | 2019-11-14 | 2019-11-14 | Astaxanthin emulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110742862A true CN110742862A (en) | 2020-02-04 |
Family
ID=69283102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911110978.2A Pending CN110742862A (en) | 2019-11-14 | 2019-11-14 | Astaxanthin emulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110742862A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112515053A (en) * | 2020-11-02 | 2021-03-19 | 无锡泓宝微生物科技有限公司 | A QINGSU bacterium for enhancing pigment and immunity of aquatic animal |
| CN112617027A (en) * | 2020-12-31 | 2021-04-09 | 上海泓宝绿色水产股份有限公司 | Bdelloecium bdellovii and preparation method and use method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105231333A (en) * | 2015-11-12 | 2016-01-13 | 东北农业大学 | Preparation method of DHA nutrient emulsion |
| CN105582001A (en) * | 2015-12-25 | 2016-05-18 | 南京泛成生物化工有限公司 | Astaxanthin composition, preparation and preparation method of composition |
| CN107279992A (en) * | 2017-06-02 | 2017-10-24 | 杭州鑫伟低碳技术研发有限公司 | It is a kind of to be used to protect astaxanthin product of eyesight improving memory and preparation method thereof |
| WO2018214914A1 (en) * | 2017-05-23 | 2018-11-29 | 大江生医股份有限公司 | Micron fish oil composition and preparation method and use thereof |
| CN110269254A (en) * | 2018-12-12 | 2019-09-24 | 浙江九旭药业有限公司 | A kind of whitening, anti-oxidant, strengthen immunity cream and its preparation method and application of receiving |
-
2019
- 2019-11-14 CN CN201911110978.2A patent/CN110742862A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105231333A (en) * | 2015-11-12 | 2016-01-13 | 东北农业大学 | Preparation method of DHA nutrient emulsion |
| CN105582001A (en) * | 2015-12-25 | 2016-05-18 | 南京泛成生物化工有限公司 | Astaxanthin composition, preparation and preparation method of composition |
| WO2018214914A1 (en) * | 2017-05-23 | 2018-11-29 | 大江生医股份有限公司 | Micron fish oil composition and preparation method and use thereof |
| CN107279992A (en) * | 2017-06-02 | 2017-10-24 | 杭州鑫伟低碳技术研发有限公司 | It is a kind of to be used to protect astaxanthin product of eyesight improving memory and preparation method thereof |
| CN110269254A (en) * | 2018-12-12 | 2019-09-24 | 浙江九旭药业有限公司 | A kind of whitening, anti-oxidant, strengthen immunity cream and its preparation method and application of receiving |
Non-Patent Citations (2)
| Title |
|---|
| 潘卫三主编: "《工业药剂学》", 31 August 2015, 中国医药科技出版社 * |
| 王丹等: "鱼油类保健食品中维生素E检测的乳化原因分析及改进建议", 《卫生研究》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112515053A (en) * | 2020-11-02 | 2021-03-19 | 无锡泓宝微生物科技有限公司 | A QINGSU bacterium for enhancing pigment and immunity of aquatic animal |
| CN112617027A (en) * | 2020-12-31 | 2021-04-09 | 上海泓宝绿色水产股份有限公司 | Bdelloecium bdellovii and preparation method and use method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9200236B2 (en) | Omega 7 rich compositions and methods of isolating omega 7 fatty acids | |
| AU2011306471B2 (en) | Process for concentrating omega-3 fatty acids | |
| EP1238048B1 (en) | Method for purifying marine mammal oil enriched in omega 3 fatty acids and compositions comprising same | |
| CN102041166A (en) | Method for extracting krill oil with high phosphatide content from Antarctic krills | |
| CN110742862A (en) | Astaxanthin emulsion and preparation method thereof | |
| JP2022511537A (en) | Very long chain fatty acid composition | |
| US11806316B2 (en) | Food supplement | |
| Bowen-Forbes et al. | Fats | |
| Hoan et al. | The effect of different levels of sesame oil on productive performance, egg yolk and blood serum lipid profile in laying hens | |
| Topuz et al. | Characterization and emulsifying properties of aquatic lecithins isolated from processing discard of rainbow trout fish and its eggs | |
| Chow et al. | The effect of dietary carotenoids of different forms: microemulsified and non-microemulsified on the growth performance, pigmentation and hematological parameters in hybrid catfish (Clarias macrocephalus× Clarias gariepinus) | |
| JP2017532381A (en) | Monounsaturated fatty acid composition and use for treating atherosclerosis | |
| JP2012020948A (en) | Composition for emulsification | |
| JP7094816B2 (en) | Astaxanthin-containing powder | |
| US20200147147A1 (en) | Micron fish oil composition, and preparation process and uses thereof | |
| ITUB20153877A1 (en) | Method of purification of glycerides of fatty acids, compositions derived from them, and their use | |
| Hashim et al. | Preparation of concentrated polyunsaturated fatty acids (PUFA) from soybean oil | |
| Hoa et al. | Research of the composition of lipids, fatty acids, and amino acids from egg and body of sea urchin Tripneustes gratilla | |
| Valavan et al. | Production of designer egg: Effects of various n-3 lipid sources on fatty acids composition and sensory characteristics of chicken egg | |
| CN102746204B (en) | Method for using VE powder to quickly adsorb astaxanthin of antarctic krill and esters of astaxanthin and for VE separation | |
| RU2809772C2 (en) | Food supplement | |
| JP2011062093A (en) | Composition for food and/or feed | |
| US20230022483A1 (en) | Method for remediating water sources and mixtures formed from the same | |
| EP3927183A1 (en) | Food supplement | |
| Suseno et al. | Stability of shark (Centrophorus sp.) liver oil rich in squalene as an immunostimulant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200204 |